UK-headquartered Cycle Pharmaceuticals, a developer of treatments for the rare disease patient community, has completed the acquisition of US-based specialty pharma Banner Life Sciences. The deal includes Banner’s BAFIERTAM (monomethyl fumarate)…
UK: Cycle Pharmaceuticals completes acquisition of Banner Life Sciences
…
…






